No Data
Jianyin International: Raised AKESO's Target Price to 120 Hong Kong dollars, maintaining an "outperform the market" rating.
Jianyin International released a Research Report stating that it raised the Target Price for AKESO (09926) by 33.3%, from HKD 90 to HKD 120, mainly reflecting the upward revision of the company's earnings forecast and the high likelihood of the company's lung cancer pharmaceuticals achieving success in China and overseas. The rating of "Outperform Market" is maintained. The bank pointed out that AKESO has a solid fundamental outlook. On April 18, AKESO announced that its human IgG1 antibody (AK101), Ebdarokimab, has been approved for the Chinese market for the treatment of moderate to severe plaque psoriasis. This success prompted the bank to adjust AKESO's outlook.
Notable Healthcare Headlines for the Week: Merck, Roche and Bausch Health in Focus
KEYTRUDA (Pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
No Misses Here: Healthcare Earnings Sweep Past Wall Street Estimates
Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street
Analysts Have Made A Financial Statement On Merck & Co., Inc.'s (NYSE:MRK) First-Quarter Report
